
    
      Phase 1a:

      The primary objective of the phase 1a part of the study is to evaluate the safety,
      tolerability, pharmacokinetics, pharmacodynamic and anti-tumor activity of oral KF-0210 as a
      single agent in participants with advanced solid tumors, to identify the dose-limiting
      toxicity and establish the maximum tolerated dose, or maximum administered dose and/or the
      recommended Phase II dose of KF-0210 in participants with advanced solid tumors.

      Phase 1b:

      The primary objective of the phase 1b part of the study is to assess the safety,
      pharmacokinetics, pharmacodynamic and anti-tumor activity of KF-0210 in combination with
      Atezolizumab in patients with colorectal cancer (CRC) (MSS), lung cancer (LC), squamous cell
      carcinoma of the esophagus (SCCE), gastric cancer (GC), and bladder cancer (BC).
    
  